Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Stock Chart & Stats
$2.71
-$0.03(-1.20%)
At close: 4:00 PM EST
$2.71
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$1.05 - $3.48
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.11M
Market Cap
$296.87M
Enterprise Value$76.62M
Total Cash (Recent Filing)$95.91M
Total Debt (Recent Filing)$2.24M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 03, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding108,345,240
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.23
Price to Sales (P/S)10.24
P/FCF Ratio-9.49
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit21.60
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$9.25Price Target Upside241.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pharmacokinetics And DosingATI-052's long effective half-life and dose-proportional exposure support potential infrequent dosing schedules, which could improve patient adherence and commercial attractiveness.
Pipeline Breadth And Development ProgressAclaris's diversified clinical portfolio, including an anti-TSLP antibody in Phase 2 and kinase inhibitors advancing toward later-stage trials, creates multiple potential value inflection points and reduces reliance on a single program.
Safety And TolerabilityATI-052 demonstrated favorable safety across tested doses with no serious adverse events or treatment discontinuations, supporting continued clinical development.
Bears Say
Clinical Development UncertaintyConcerns about the biologic candidates' mechanisms could increase the likelihood of clinical setbacks or delays, heightening development uncertainty.
Investor Sentiment And Valuation RiskMarket skepticism toward the biologic portfolio may compress valuation multiples and limit share price upside even if select programs progress.
Target Selection RiskSkepticism about the biologic pipeline's target choices raises the risk that lead candidates may not translate into clear clinical benefits, undermining expected returns.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.05 and its highest was $3.48 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $296.87M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 47 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.016.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 108,345,240 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went down -4.237%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (241.33% Upside)
$9.25 (241.33% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
-113.23%
Trailing 12-Months
Asset Growth
17.43%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$9.25
▲(241.33% Upside)
Technical Analysis
Ownership Overview
3.04% Insiders
8.72% Mutual Funds
1.39% Other Institutional Investors
74.72% Public Companies and
Individual Investors